EIF3A and glioma: Targeting m6A reader proteins, like eIF3, to enhance radiotherapy sensitivity and modulate YTHDF, YTHDC, and HNRNP proteins to counteract chemotherapeutic resistance represents future research avenues to improve glioma treatment efficacy.